From: Bench-to-bedside review: Vasopressin in the management of septic shock
Study | Condition | Vasopressin (AVP) levels | Provasopressin | Copeptin levels |
---|---|---|---|---|
Landry and colleagues [ 48 ] | Septic shock | 3.1 pg/ml | Â | Â |
 | Cardiogenic shock | 22.7 pg/ml |  |  |
Lin and colleagues [61] | Septic shock | 3.6 pg/ml | Â | Â |
 | Sepsis | 10.6 pg/ml |  |  |
 | Severe sepsis | 21.8 pg/ml |  |  |
Jochberger and colleagues [59] | Sepsis | 11.9 pg/ml | Â | Â |
Morgenthaler and colleagues [57] | Critically ill (no sepsis) | Â | Â | 27 pM |
 | Sepsis |  |  | 50 pM |
 | Severe sepsis |  |  | 74 pM |
 | Septic shock |  |  | 171 pM |
Lodha and colleagues [64] | Pediatric septic shock | 116 pg/ml | Â | Â |
 | Pediatric severe sepsis | 106 pg/ml |  |  |
 | Multiple trauma | 44.3 pM |  |  |
Russell and colleagues [52] | Septic shock | 3.2 pM | Â | Â |
 | Septic shock plus vasopressin infusion (0.03 U/minute) at 6 hours | 74 pM |  |  |
 | Septic shock plus vasopressin infusion (0.03 U/minute) at 24 hours | 98 pM |  |  |
Jochberger and colleagues [53] | Infection | 3.2 pM* | Â | 25 pM* |
 | Severe sepsis | 6.5 pM* |  | 60 pM* |
 | Septic shock | 6.4 pM* |  | 70 pM* |
Sharshar and colleagues[138] | Septic shock | 1.6, 1.8, 16 pg/ml | Â | Â |
 |  | Low neurophypophyseal T1 (AVP) |  |  |
 | Neurohypophyseal levels of AVP |  |  |  |
Sharshar and colleagues [139] | Septic shock | X | Â | Â |
Le Clerc and colleagues [140] | Pediatric meningococcal shock | X | Â | Â |
Kruger and colleagues [141] | Community-acquired pneumonia | Â | Â | Â |
 | Antibiotic pretreatment |  |  | 12.8 pmol/l |
 | Community-acquired pneumonia |  |  |  |
 | No antibiotic pretreatment |  |  | 20. 8 pmol/l |
de Kruif and colleagues [142] | Pre Escherichia coli endotoxin in humans | Â | 12.5 pmol/l | Â |
 | Peak E. coli endotoxin in humans |  | 18.0 pmol/l |  |
 | Prednisone 10 mg pretreatment. Peak E. coli endotoxin in humans |  | 10.6 pmol/l |  |
 | Prednisone 30 mg pretreatment. Peak E. coli endotoxin in humans |  | 6.1pmol/l |  |